UNSPSC 51282907: Binfloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78VM28ZA2H, chemically known as 7-(1,4-diazabicyclo(3.2.2)non-4-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid but generally known as binfloxacin, which bears US NIH Compound Identifier 166565. European Medicines Agency schedules Binfloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05836MIG.

UNSPSC 51282907 Binfloxacin is a Commodity code that nominally refers to a specific fluoroquinolone antibiotic; however, recent state and local solicitations tagged under this code do not reflect binfloxacin procurement. Instead, the code appears in opportunities for broader pharmaceutical and medical supply purchasing, including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, medical and first aid supplies for emergency response, and exploratory direct-to-manufacturer prescription programs. State and local governments are using this code to tag acquisitions of emergency medical consumables, pharmacy benefit programs, and bulk pharmaceutical sourcing rather than binfloxacin specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration), municipalities (City of Tampa), and multistate cooperative purchasing alliances (MMCAP). The mix reflects both single-jurisdiction procurement and larger cooperative vehicles designed to aggregate demand across multiple states and localities.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with multistate cooperation extending beyond individual state boundaries. Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response date; the City of Tampa's March 13, 2026 bid for medical and first aid supplies (169 line items, $700,000 estimated value) sheltered to certified Small Local Business Enterprises; the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, serving state and local facilities across multiple states; and the Texas HHS Commission's April 3, 2026 Request for Information on direct-to-manufacturer prescription programs. The wide variance between the code's nominal scope and the work actually being solicited suggests either broad agency tagging practices or a mislabeling issue in the source data; pursue with caution and verify code-level applicability in the solicitation documents themselves.